iHateHospitals.com

MEDICAL NEWS:
Abstract

Background  African-American women have the highest breast (boob) cancer death rates of all racial/ethnic groups in the US. Reasons for these
disparities are multi-factorial, but include lower mammogram utilization among this population. Cultural attitudes and beliefs,
such as fear and fatalism, have not been fully explored as potential barriers to mammography among African-American women.

Objective  To [...]

CANCER NEWS: Well, it has been a couple months since we posted anything here…..you know it really is true…life does go on! Valerie had implants put in last October, and with all the changes her body went through after Chemo and Radiation, they (the implants) have decided not to cooperate. So, Valerie is scheduled [...]

CANCER NEWS: The hypothesis that cancer stem cells are responsible for the chemo-resistant and metastatic phenotypes of many breast (women’s) cancers has gained support using cell sorting strategies to enrich for the tumor-initiating population of cells. However, the mechanisms regulating the cancer stem cell pool are less clear. Two recent publications suggest that loss [...]

CANCER NEWS: Well, it has been a couple months since we posted anything here…..you know it really is true…life does go on! Valerie had implants put in last October, and with all the changes her body went through after Chemo and Radiation, they (the implants) have decided not to cooperate. So, Valerie is scheduled [...]

CANCER NEWS: As of early Sunday morning, Jill Biden took on a new title: possible Vice Presidential wife. (“Second Lady” sounds so tacky, doesn’t it?) And if she and husband Joe move into Blair House come January 2009, she’ll assume a whole new set of responsibilities. But I’m betting she’ll keep a firm grip [...]

CANCER NEWS: Not all doctors email patients, nor for that matter do all doctors email each other - but I have found it to be helpful for many patients. Not all patients have my email account, but for some patients for whom it seems appropriate I have given out my office email adDr. [...]

CANCER NEWS: IntroductionPatients with primary operable estrogen receptor negative (ER-) breast (women’s) cancer account for approximately 30% of all cases and generally have worse prognosis (outlook) than ER+ patients. Nevertheless, a significant proportion of ER- cases have favourable outcome and could potentially benefit from a less aggressive course of therapy. Identification of such good [...]

CANCER NEWS: Australian scientists have identified a way to ’switch off’ a molecule, a key player in the molecular processes that trigger breast (women’s) cancer and certain forms of leukemia. The molecule, known as Gab2, operates downstream of a major breast (women’s) cancer oncogene, HER2, the target of the Dr. (God)g Herceptin. A research [...]

CANCER NEWS: COPENHAGEN, Denmark — Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Genmab A/S announced today plans to begin four studies of ofatumumab in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin’s lymphoma (NHL) this year. “Genmab and GSK have worked diligently to expand the [...]

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

CANCER NEWS: PALO ALTO, Calif. — Telik, Inc. announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome [...]

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]